HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cavaletti, G. Articles by Zanna, C. Search for Related Content PubMed PubMed Citation Articles by Cavaletti, G. Articles by Zanna, C. Related Collections Peripheral neuropathy All Oncology Chemotherapy-tumor

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

From the Dipartimento di Neuroscienze e Tecnologie Biomediche (Drs. Cavaletti and Piatti) and Dipartimento di Scienze Chirurgiche (Drs. Lissoni and Fei), Università di Milano "Bicocca," Monza; Clinica Neurologica (Drs. Bogliun, Marzorati, Zincone, and Piatti) and Clinica Ginecologica (Drs. Lissoni and Fei), A.O. S. Gerardo, Monza; Dipartimento di Ginecologia Oncologica (Drs. Colombo and Parma), Istituto Europeo di Oncologia, Milan; and Sigma-Tau ifr (Drs. Cundari and Zanna), Pomezia, Italy.

Address correspondence and reprint requests to Prof. Guido Cavaletti, Clinica Neurologica–Ospedale S. Gerardo, v. Donizetti 106, 20052 Monza (MI), Italy; e-mail: guido.cavaletti{at}unimib.it

The authors compared clinically based neurotoxicity scales with the Total Neuropathy Scale, with the aim of improving the grading of the severity of chemotherapy-induced peripheral neuropathy (CIPN). The severity of CIPN was evaluated in a series of 60 women treated with cisplatin- and paclitaxel-based chemotherapy. A reduced version of TNS (TNSr) was also compared. The authors concluded that the TNS and TNSr can be used to assess the severity of CIPN effectively, and the results of this evaluation can be reliably correlated with the oncologic grading of sensory peripheral neurotoxicity.

Received April 16, 2003. Accepted in final form July 10, 2003.

This article has been cited by other articles:

				K. Kuroi, K. Shimozuma, Y. Ohashi, A. Takeuchi, T. Aranishi, S. Morita, S. Ohsumi, T. Watanabe, S. Bain, and F. H. Hausheer A Questionnaire Survey of Physicians' Perspectives Regarding the Assessment of Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 748 - 754. [Abstract] [Full Text] [PDF]

				A. A. Argyriou, G. Iconomou, and H. P. Kalofonos Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood, September 1, 2008; 112(5): 1593 - 1599. [Abstract] [Full Text] [PDF]

				I. D. Davis, L. Kiers, L. MacGregor, M. Quinn, J. Arezzo, M. Green, M. Rosenthal, M. Chia, M. Michael, P. Bartley, et al. A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy Clin. Cancer Res., March 1, 2005; 11(5): 1890 - 1898. [Abstract] [Full Text] [PDF]

				G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Piatti, N. Colombo, D. Franchi, M. T. La Presa, A. Lissoni, A. Buda, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy Ann. Onc., September 1, 2004; 15(9): 1439 - 1442. [Abstract] [Full Text] [PDF]